Disease · MONDO_0005055

Kaposi's sarcoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. Kaposi's sarcoma. Diseases, record MONDO_0005055. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005055

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: Kaposi's sarcoma; Open Targets
Open Targets ID: MONDO_0005055; Open Targets
Other names: KS, Kaposi sarcoma, Kaposi's sarcoma (disease), Kaposi's sarcoma of conjunctiva, Kaposi's sarcoma of cornea, Kaposi's sarcoma of lung, Kaposi's sarcoma of palate, Kaposi's sarcoma of soft tissue, Kaposi's sarcoma of soft tissues; Open Targets
Disease Ontology: DOID:8632; Disease Ontology
MeSH: D012514; MeSH
NCI Thesaurus: C9087; NCI Thesaurus
Orphanet: ORPHA:33276; Orphanet
Highest stage of its drugs: Approval, for 6 of its 80 drugs, from DailyMed, EMA Human Drugs, FDA, PMDA and TTD; Open Targets

Drugs80

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
DOXORUBICIN	CHEMBL53463	Small molecule	Approval	EMA Human Drugs	13	10	10	Drugs and targets
DOXORUBICIN HYDROCHLORIDE	CHEMBL359744	Small molecule	Approval	DailyMed and PMDA	11	8	8	Drugs and targets
PACLITAXEL	CHEMBL428647	Small molecule	Approval	EMA Human Drugs, at withdrawal	7	6	6	Drugs and targets
ALITRETINOIN	CHEMBL705	Small molecule	Approval	TTD	4	2	2	Drugs and targets
DAUNORUBICIN	CHEMBL178	Small molecule	Approval	TTD	3	2	2	Drugs and targets
INTERFERON ALFA-2B	CHEMBL1201558	Protein	Approval	FDA	3	2	2	Drugs and targets
ZIDOVUDINE	CHEMBL129	Small molecule	Phase 3	ClinicalTrials.gov	10	10	10	Drugs and targets
BLEOMYCIN	CHEMBL6067492		Phase 3	ClinicalTrials.gov	7	7	7	Drugs and targets
VINCRISTINE	CHEMBL90555	Small molecule	Phase 3	ClinicalTrials.gov	6	6	6	Drugs and targets
BLEOMYCIN SULFATE	CHEMBL6067493		Phase 3	ClinicalTrials.gov	5	5	5	Drugs and targets

1 to 10 of 80

See all 80 drugs

Targets124

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
TOP2A	DNA topoisomerase 2-alpha	7	DNA topoisomerase II alpha inhibitor; DNA topoisomerase II inhibitor	Approval	https://conductscience.org/library/genes/7153	Drugs and targets
KDR	Vascular endothelial growth factor receptor	5	Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/3791	Drugs and targets
FLT1	Vascular endothelial growth factor receptor	4	Vascular endothelial growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/2321	Drugs and targets
FLT4	Vascular endothelial growth factor receptor	4	Vascular endothelial growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/2324	Drugs and targets
KIT	Mast/stem cell growth factor receptor Kit	4	Stem cell growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/3815	Drugs and targets
TUBA1A	Tubulin	4	Tubulin inhibitor	Approval	https://conductscience.org/library/genes/7846	Drugs and targets
TUBA1B	Tubulin	4	Tubulin inhibitor	Approval	https://conductscience.org/library/genes/10376	Drugs and targets
TUBA1C	Tubulin	4	Tubulin inhibitor	Approval	https://conductscience.org/library/genes/84790	Drugs and targets
TUBA3C	Tubulin	4	Tubulin inhibitor	Approval	https://conductscience.org/library/genes/7278	Drugs and targets
TUBA3E	Tubulin	4	Tubulin inhibitor	Approval	https://conductscience.org/library/genes/112714	Drugs and targets

1 to 10 of 124

See all 124 targets

Trials105

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01435018	Three Chemo Regimens as an Adjunct to ART for Treatment of Advanced AIDS-KS	Phase 3	334	2019-04-08	HIV-1 Infection	BLEOMYCIN, EFAVIRENZ, EMTRICITABINE, EMTRICITABINE, (+/-)-, ETOPOSIDE, PACLITAXEL, TENOFOVIR DISOPROXIL FUMARATE, VINCRISTINE	Its record names the disease	ClinicalTrials.gov
NCT01352117	Antiretroviral Therapy (ART) Alone or With Delayed Chemo Versus ART With Immediate Chemo for Limited AIDS-related Kaposi's Sarcoma	Phase 3	192	2017-07-31	HIV-1 Infection, Kaposi's Sarcoma	EFAVIRENZ, EMTRICITABINE, ETOPOSIDE, TENOFOVIR DISOPROXIL FUMARATE	Its record names the disease	ClinicalTrials.gov
NCT02595866	Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer	Phase 1	58	2024-07-16	AIDS-Related Non-Hodgkin Lymphoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Hepatocellular Carcinoma, HIV Infection, Kaposi Sarcoma, Locally Advanced Lung Non-Small Cell Carcinoma, Locally Advanced Malignant Solid Neoplasm, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Non-Hodgkin Lymphoma, Recurrent Classic Hodgkin Lymphoma, Recurrent Malignant Neoplasm, Refractory Classic Hodgkin Lymphoma, Refractory Malignant Neoplasm, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Unresectable Melanoma	PEMBROLIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT03296553	Impact of Valganciclovir on Severe IRIS-Kaposi Sarcoma Mortality: an Open-label, Parallel, Randomized Controlled-trial.	Phase 2	40	2022-01-27	Kaposi Sarcoma, Human Immunodeficiency Virus, Immune Reconstitution Syndrome	BLEOMYCIN, VALGANCICLOVIR, VINCRISTINE	Its record names the disease	ClinicalTrials.gov
NCT01057121	Lenalidomide in Treating Patients With AIDS-Associated Kaposi's Sarcoma	Phase 1/2	38	2016-07-21	AIDS-Related Kaposi Sarcoma, Recurrent Kaposi Sarcoma	LENALIDOMIDE	Its record names the disease	ClinicalTrials.gov
NCT03077451	Nelfinavir Mesylate in Treating Patients With Kaposi Sarcoma	Phase 2	36	2024-02-02	Recurrent Kaposi Sarcoma, Skin Kaposi Sarcoma	NELFINAVIR MESYLATE	Its record names the disease	ClinicalTrials.gov
NCT00090987	Imatinib Mesylate in Treating Patients With HIV-Related Kaposi's Sarcoma	Phase 2	30	2011-07-26	Sarcoma	IMATINIB MESYLATE	Its record names the disease	ClinicalTrials.gov
NCT01495598	Pomalidomide for Kaposi Sarcoma in People With or Without HIV	Phase 1/2	28	2022-11-01	Kaposi Sarcoma, Sarcoma, Kaposi	POMALIDOMIDE	Its record names the disease	ClinicalTrials.gov
NCT03601806	Pomalidomide in Treating Patients With Kaposi Sarcoma and Human Immunodeficiency Virus Infection	Phase 2	26	2026-02-02	Human Immunodeficiency Virus 1 Positive, Skin Kaposi Sarcoma	POMALIDOMIDE	Its record names the disease	ClinicalTrials.gov
NCT00055237	Bevacizumab to Treat Kaposi's Sarcoma in HIV-Positive and HIV-Negative Patients	Phase 2	19	2012-07-26	Kaposi's Sarcoma, HIV Infections, HIV Seronegativity	BEVACIZUMAB	Its record names the disease	ClinicalTrials.gov

1 to 10 of 105

See all 105 trials

Comparisons in its trials19

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
BV+ART vs PTX+ART: Number of Participants With Objective Response for BV+ART vs. PTX+ART	80 of 132	91 of 138	270	NCT01435018	Trial comparisons
BV+ART vs PTX+ART: Number of Participants With Kaposi's Sarcoma-Immune Reconstitution Inflammatory Syndrome (KS-IRIS) for BV+ART vs. PTX+ART	2 of 132	0 of 138	270	NCT01435018	Trial comparisons
Arm A: ART Alone or With Delayed ET vs Arm B: ART With Immediate ET: Number of Participants With Grade 3 or Higher Adverse Events	47 of 94	42 of 96	190	NCT01352117	Trial comparisons
Arm A: ART Alone or With Delayed ET vs Arm B: ART With Immediate ET: deaths from any cause	15 of 94	16 of 96	190	NCT01352117	Trial comparisons
Arm A: ART Alone or With Delayed ET vs Arm B: ART With Immediate ET: serious adverse events	34 of 94	34 of 96	190	NCT01352117	Trial comparisons
ET+ART vs PTX+ART: Number of Participants With Kaposi's Sarcoma-Immune Reconstitution Inflammatory Syndrome (KS-IRIS) for ET+ART vs. PTX+ART	6 of 59	0 of 59	118	NCT01435018	Trial comparisons
ET+ART vs PTX+ART: Number of Participants With Objective Response for ET+ART vs. PTX+ART	18 of 59	34 of 59	118	NCT01435018	Trial comparisons
High Dose Treatment After Receiving the Standard Dose (Nelfinavir Mesylate) vs Standard Dose Treatment (Nelfinavir Mesylate): deaths from any cause	0 of 31	0 of 36	67	NCT03077451	Trial comparisons
High Dose Treatment After Receiving the Standard Dose (Nelfinavir Mesylate) vs Standard Dose Treatment (Nelfinavir Mesylate): serious adverse events	1 of 31	0 of 36	67	NCT03077451	Trial comparisons
Valganciclovir vs Antiretroviral Combinations: Number of Participants Who Died of Immune Reconstitution Inflammatory Syndrome Associated to Kaposi Sarcoma (IRIS-KS)	0 of 20	3 of 20	40	NCT03296553	Trial comparisons

1 to 10 of 19

See all 19 comparisons in its trials

Papers from its trials30

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
34862247	RESULT	1	PubMed
32145827	RESULT	1	PubMed
29365083	RESULT	1	PubMed
27863194	RESULT	1	PubMed
25970141	RESULT	1	PubMed
22430271	RESULT	1	PubMed
18384551	RESULT	1	PubMed
18224669	RESULT	1	PubMed
17846226	RESULT	1	PubMed
10893291	RESULT	1	PubMed

1 to 10 of 30

See all 30 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005055

GET https://conductscience.org/api/diseases/v1/MONDO_0005055/drugs?page=2

API reference For AI assistants